skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant

Original Research

(962) Views  (151) Full article downloads

Authors: Sheppard Jr JD, Nguyen QD, Usner DW, Comstock TL; Fluocinolone Acetonide Uveitis Study Group

Published Date January 2012 Volume 2012:6 Pages 79 - 85
DOI: http://dx.doi.org/10.2147/OPTH.S24397

John D Sheppard Jr1, Quan Dong Nguyen2, Dale W Usner3, Timothy L Comstock3, for the Fluocinolone Acetonide Uveitis Study Group
1Eastern Virginia Medical School, Norfolk, VA, USA; 2Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, MD, USA; 3Bausch and Lomb Incorporated, Rochester, NY, USA

Purpose: To describe visual acuity (VA) and inflammation following cataract surgery in eyes with noninfectious posterior uveitis (NIPU) that were being treated with a fluocinolone acetonide (FA) intravitreal implant compared with those that were not.
Design: Post hoc, subgroup analysis of data from a 3-year, dose-masked, randomized, multicenter trial evaluating the FA implant for the treatment of NIPU.
Participants and controls: The subset of eyes that underwent cataract surgery during the 3-year trial. Eyes were either implanted with a 0.59- or a 2.1-mg FA implant, or, in the case of affected fellow eyes, received standard-of-care local treatment.
Main outcome measures: VA, anterior and posterior chamber inflammation at 1 and 3 months after surgery, and rate of uveitis recurrence and serious postoperative ocular adverse events.
Results: Of 278 patients enrolled in the main trial, 132/142 phakic implanted eyes and 39/186 phakic non-implanted eyes underwent cataract surgery. Mean improvement in VA was significantly greater in implanted than non-implanted eyes at 1 (P = 0.0047) and 3 months (P = 0.0015) postoperatively; significantly fewer anterior chamber cells were seen in implanted than non-implanted eyes at 1 (P = 0.0084) and 3 months (P = 0.0002). Severity of vitreous haze was less in implanted than non-implanted eyes at 3 months postoperatively (P = 0.0005). The postsurgical uveitis recurrence rate was lower in implanted than non-implanted eyes (26.5% vs 44.4%; P = 0.0433). Glaucoma was reported in 19.7% of implanted eyes and no non-implanted eyes (P = 0.0008) postoperatively.
Conclusion: In this post hoc subgroup analysis, eyes with NIPU treated with the FA intravitreal implant demonstrated better vision and less intraocular inflammation following cataract surgery than non-implanted eyes. Recurrent uveitic inflammation did not appear to be triggered by cataract surgery. Glaucoma occurred more frequently in implanted eyes.

Keywords: cataract surgery, posterior chamber inflammation, glaucoma, intraocular pressure, visual acuity, steroid implant






Readers of this article also read:

Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
Long term result of silicone oil versus gas tamponade in the treatment of traumatic macular holes
Multipurpose soft contact lens care in Japan
Serological IgG avidity test for ocular toxoplasmosis
Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation
Visual performance in cataract patients with low levels of postoperative astigmatism: full correction versus spherical equivalent correction
An evaluation of the accuracy of the ORange® (Gen II) by comparing it to the IOLMaster® in the prediction of postoperative refraction
Pneumatic tools for vitreoretinal surgery
Optic neuritis in a child with biotinidase deficiency case report and literature review
Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis